Immediate Impact
1 by Nobel laureates 3 from Science/Nature 82 standout
Citing Papers
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Works of Jeannette E. Mares being referenced
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jeannette E. Mares | 3262 | 3544 | 2334 | 13 | 3.8k | |
| Cecile G. Dagohoy | 3280 | 3559 | 2320 | 14 | 3.8k | |
| Colleen Leary | 3312 | 3661 | 2437 | 11 | 3.9k | |
| Kevin D. Lye | 1755 | 2084 | 1387 | 19 | 2.4k | |
| Anja Rinke | 3763 | 4094 | 3033 | 93 | 4.3k | |
| Sakina Hoosen | 2103 | 2116 | 1446 | 7 | 2.8k | |
| A. M. McNicol | 2375 | 1878 | 1201 | 39 | 3.1k | |
| Birgitte Federspiel | 2243 | 2432 | 1610 | 74 | 3.5k | |
| Jan Harder | 2158 | 1770 | 1298 | 27 | 2.9k | |
| M. Wied | 2016 | 2237 | 1735 | 13 | 2.3k | |
| Shem Patyna | 1845 | 1517 | 1120 | 32 | 2.5k |
All Works
Loading papers...